TP53 and breast carcinoma: A study of Basma et al., (Figure 2(7)) shows that the effects of delivering bcl-2 antisense and CDDP combination therapy in breast carcinoma cells p53(+)MCF-7 and p53(−)MCF-7/E6 significantly increased, apoptosis, and cytochrome c release in MCF-7/E6 than in MCF-7, but did not affect Fas levels and activated caspase-8.